CJC-1295 vs Sermorelin

Same class, different durability

CJC-1295 vs Sermorelin is a comparison within a single drug class. Both are synthetic analogs of growth-hormone-releasing hormone, and both act on the same GHRH receptor on pituitary somatotrophs to stimulate the body's own GH release ^[2]. Sermorelin is essentially GHRH(1-29) — the active fragment itself — and like native GHRH it is cleared rapidly, on a minutes timescale, which is why sermorelin protocols historically called for frequent administration. CJC-1295 starts from the same 29-residue backbone but adds the four protease-resistant substitutions and, in the DAC form, the covalent albumin tether ^[2].

The consequence is durability. Where sermorelin is short-lived, CJC-1295 DAC carried an estimated 5.8-8.1 day half-life in healthy adults, holding GH elevated for days and IGF-1 for nine to eleven days from a single dose ^[1]. In the same class, CJC-1295 is the long-acting member and sermorelin is the short-acting one — a difference of pharmacokinetic engineering, not of receptor target. It is worth noting that the no-DAC form of CJC-1295, Modified GRF (1-29), sits much closer to sermorelin on the duration axis: both are short-acting GHRH(1-29)-based peptides, and the dramatic half-life gap is specifically a property of the DAC variant, not of the CJC-1295 name as such.

Where the evidence stands for each

The two analogs also differ in regulatory and evidentiary standing. Sermorelin has a history as an approved GHRH analog. CJC-1295 is an unapproved research chemical with a human record limited to early-phase pharmacokinetic studies in healthy volunteers ^[1][3]; there are no large efficacy or long-term safety trials in healthy adults, and the long-acting DAC development program was discontinued. A 2025 Nature Reviews Endocrinology review covers the GHRH-analog class as a whole — including sermorelin, tesamorelin, and CJC-1295 — describing receptor signaling and the rationale for long-acting analog design ^[10].

Sermorelin is named here only as a generic GHRH analog for comparison; this site makes no claim about either compound as a treatment and recommends nothing.

Tesamorelin: the approved-analog benchmark

The closest approved-drug comparator to CJC-1295 is tesamorelin, another GHRH analog. It is useful as a benchmark for what GHRH-axis stimulation looks like when it has been carried through controlled trials: a randomized trial confirmed tesamorelin's effects on visceral adiposity and metabolic endpoints in patients with excess abdominal fat ^[12], and a 2026 analysis reported its body-composition, hepatic-fat, metabolic, and safety outcomes ^[13]. Tesamorelin is not CJC-1295 and is not interchangeable with it; it is cited here because its trial record is the kind of evidence base CJC-1295 does not have, which is itself the most honest point of the comparison.

How to use this comparison

Read this comparison as a map of evidence, not a recommendation between options. All three compounds — sermorelin, tesamorelin, and CJC-1295 — share a receptor and a broad mechanism, but they sit at very different points on two axes: duration of action and depth of human evidence. Sermorelin and tesamorelin have regulatory histories and, for tesamorelin, a controlled-trial record. CJC-1295's appeal in the popular literature is its multi-day duration from a single dose ^[1], but that convenience is paired with the thinnest human evidence base of the three.

The most useful takeaway is structural. If a source treats CJC-1295 as simply "a stronger sermorelin," it is collapsing a real difference: the receptor target is shared, but the pharmacokinetics, the regulatory status, and the size of the human record are not. This site keeps those apart, and points the deeper pharmacokinetic split to the CJC-1295 DAC vs no-DAC page, where the long and short forms of CJC-1295 itself are separated.